Dennis Cho Sells 412 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Key Points

• Insider sale: Dennis Cho sold 412 Twist Bioscience shares for approximately $50,519 at an average price of $122.62 to cover tax withholding tied to vested equity awards. He retained 73,651 shares, and the sale reduced his ownership by 0.56%.
• Stock performance: Twist shares recently traded at $126.85, near the upper end of their 52-week range of $23.30 to $155.44. The company has a $7.95 billion market capitalization but remains unprofitable, with a negative price-to-earnings ratio and projected full-year EPS of -$2.12.
• Business and analyst outlook: Quarterly revenue rose 23.2% year over year to $118.38 million, though adjusted EPS missed expectations. Analysts maintain a “Moderate Buy” consensus, with a $98.45 average price target, below the recent share price.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) insider Dennis Cho sold 412 shares of the company's stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $122.62, for a total transaction of $50,519.44. Following the completion of the transaction, the insider owned 73,651 shares in the company, valued at approximately $9,031,085.62. This represents a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dennis Cho also recently made the following trade(s):

• On Wednesday, June 24th, Dennis Cho sold 14,205 shares of Twist Bioscience stock. The shares were sold at an average price of $89.75, for a total transaction of $1,274,898.75.
• On Monday, June 22nd, Dennis Cho sold 346 shares of Twist Bioscience stock. The stock was sold at an average price of $87.32, for a total transaction of $30,212.72.

Twist Bioscience Stock Performance

Shares of NASDAQ TWST traded up $1.33 during trading hours on Thursday, reaching $126.85. 1,284,904 shares of the stock were exchanged, compared to its average volume of 1,530,816. The firm has a market capitalization of $7.95 billion, a price-to-earnings ratio of -57.14 and a beta of 2.22. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $155.44. The stock's fifty day simple moving average is $112.40 and its 200 day simple moving average is $78.44.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The firm had revenue of $118.38 million during the quarter, compared to the consensus estimate of $114.55 million. During the same quarter last year, the firm earned $0.33 earnings per share. The business's revenue for the quarter was up 23.2% compared to the same quarter last year. Sell-side analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Institutional Investors Weigh In On Twist Bioscience

Hedge funds have recently modified their holdings of the company. Allworth Financial LP acquired a new position in Twist Bioscience in the 2nd quarter worth about $62,000. Trifecta Capital Advisors LLC bought a new stake in shares of Twist Bioscience during the second quarter worth about $63,000. Western Wealth Management LLC bought a new stake in Twist Bioscience during the 1st quarter worth approximately $31,000. Strs Ohio acquired a new position in shares of Twist Bioscience during the first quarter worth $33,000. Finally, GAMMA Investing LLC grew its stake in shares of Twist Bioscience by 24.4% in the second quarter. GAMMA Investing LLC now owns 943 shares of the company's stock worth $97,000 after purchasing an additional 185 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. TD Cowen restated a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 3rd. Leerink Partners set a $110.00 target price on shares of Twist Bioscience in a report on Thursday, July 16th. Canaccord Genuity Group lifted their price objective on shares of Twist Bioscience from $90.00 to $120.00 and gave the company a "buy" rating in a research note on Tuesday, July 14th. UBS Group assumed coverage on Twist Bioscience in a report on Wednesday. They issued a "neutral" rating and a $144.00 target price on the stock. Finally, Evercore cut Twist Bioscience from an "outperform" rating to an "in-line" rating and set a $102.00 price target for the company. in a report on Monday, July 6th. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Twist Bioscience currently has an average rating of "Moderate Buy" and a consensus price target of $98.45.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.